ReviewOncogene2015
The origin of breast tumor heterogeneity.
Review in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed.
- Transcriptomic Profile of Breast Tissue of Premenopausal Women Following Treatment with Progesterone Receptor Modulator: Secondary Outcomes of a Randomized Controlled Trial.International journal of molecular sciences · 2024Trial
- BCL11B predetermines a persister state in breast cancer that is reversed by TNFα.Science advances · 2026Article
- Adipose-mimetic granular hydrogels uncover biophysical cues driving breast cancer invasion.Cell biomaterials · 2026Article
- Gap junction communication regulates luminal-myoepithelial crosstalk and cell differentiation in a bilayered human mammary epithelial cell model.Biology methods & protocols · 2026Article
- CancerSubtypeXplore: A Modular Platform for Multiomics Cancer Subtype Prediction and Biomarker Consensus Discovery.Computational and structural biotechnology journal · 2026Article
- Adipose-mimetic granular hydrogels uncover biophysical cues driving breast cancer invasion.bioRxiv : the preprint server for biology · 2025Article
- The pleiotropic roles of non-hormonal receptor basigin and regulatory microRNAs in breast cancer.NPJ breast cancer · 2025Review
- Sumoylated Etv1 establishes mouse mammary cancer stem cells that support tumorigenesis by non-stem cancer cells.Developmental cell · 2025Article
- Reactivation of Multipotency in the Mammary Gland - a Ripple in the Pond and a Turn of the Tide.Journal of mammary gland biology and neoplasia · 2025Review
- Multidisciplinary discussion on phenotypical characterization of metastatic breast cancer and patient pathway optimization from an expert panel across South Italian regions.Scientific reports · 2025Article
- First‑line endocrine therapy for hormone receptor positive and HER‑2 negative metastatic breast cancer: A Bayesian network meta‑analysis.Oncology letters · 2024Article
- Review
- Increased prevalence of hybrid epithelial/mesenchymal state and enhanced phenotypic heterogeneity in basal breast cancer.iScience · 2024Article
- Tumor suppressor FRMD3 controls mammary epithelial cell fate determination via notch signaling pathway.Science advances · 2024Article
- Assessing transcriptomic heterogeneity of single-cell RNASeq data by bulk-level gene expression data.BMC bioinformatics · 2024Article
- Article
- Discordance of Biomarker Expression Profile between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis in Preoperative Core Needle Biopsy.Diagnostics (Basel, Switzerland) · 2024Article
- Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Review
- Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors.bioRxiv : the preprint server for biology · 2023Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
How breast diversity is generated is a fascinating and fundamental question with important clinical implications. It is clear that the diversity of phenotypes displayed by breast cancer cells reflects the array of cell types present in the disease-free breast epithelium, including luminal, basal and stem cells. Therefore, it is hypothesized that the molecular regulators governing normal development of the breast epithelium may double as engines of breast tumor diversity. In the past few years, a deepened understanding of the mammary epithelial hierarchy has prompted the search for the cellular precursors of breast tumors. At the same time, the use of novel experimental strategies including the new technology of massively parallel sequencing has provided insight into the origin and evolution of breast tumors. Here, we review the current understanding of the basis of the intrinsic subtypes and the sources of inter-tumor heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.